Financial research concept

Medical Devices Neuromodulation Comparable Sales Growth

measures comparable sales growth in Abbott's Neuromodulation medical-device franchise.

By Lee BaileyPublished Oct 2, 2026

Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date: Oct 2, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context: 10 connected conceptsPart of the reviewed Medical Device Portfolio Growth; issuer definitions remain distinct where disclosed.
Company examples: 1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.

Franchise growth lagged the broader portfolio
Geography moved in opposite directions
Part of the Medical Device Portfolio Growth
See It in Company Research
Continue Research

Medical Devices Neuromodulation comparable sales growth measures year-over-year growth in Abbott's Neuromodulation franchise on the company's comparable basis.

Abbott reported 1.2% comparable sales growth in Neuromodulation in the second quarter of 2026.

Franchise growth lagged the broader portfolio

Total Medical Devices comparable growth was 8.4% in the same quarter.

That makes Neuromodulation a useful counterweight when analyzing portfolio breadth rather than focusing only on the fastest-growing franchises.

Geography moved in opposite directions

Abbott reported a 2.1% comparable decline in the U.S. and 11.3% comparable growth internationally.

Read it with Medical Devices geographic comparable growth and Medical Devices comparable growth.

Primary source: Abbott Q2 2026 earnings release filed with the SEC.

Part of the Medical Device Portfolio Growth

Connects Abbott's comparable Medical Devices growth with franchise-level growth, continuous glucose monitoring, geographic mix and the 2026 Electrophysiology/Structural Heart reclassification.

Browse the full operating model in Company Analysis →

Where this concept fits

Cardiovascular franchise mixCurrent relationship
Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, and Neuromodulation growth show which cardiovascular and neuromodulation franchises are driving or lagging total Medical Devices growth.
Electrophysiology Growth Heart Failure GrowthNeuromodulation GrowthCurrent conceptRhythm Management Growth Structural Heart Growth Vascular Growth
Portfolio and geographic growth
Total Medical Devices comparable sales growth provides the portfolio baseline, while U.S. versus international comparable growth shows how the aggregate result is distributed geographically.
Medical Devices Comparable Growth U.S. vs. International Growth
Diabetes and continuous glucose monitoring
Diabetes Care growth captures the broader franchise, while CGM comparable growth isolates the continuous-glucose-monitor platform that drives much of the franchise's expansion.
CGM Comparable Growth Diabetes Care Growth

See It in Company Research

These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.

ABTOpen operating-model research →10 of 10 reviewed concepts in Medical Device Portfolio GrowthCardiovascular franchise mix6 of 6 bridge concepts supportedContinue through this bridge:Electrophysiology Growth Heart Failure Growth Rhythm Management Growth Structural Heart Growth Vascular Growth

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare medical device portfolio growth

Compare slower Neuromodulation growth and its opposing U.S. and international trends.

Continue research

Explore more topics in the Financial Research Encyclopedia.